文献速递免疫规划传染病防控与疫情报告

Ad5载体HIV疫苗受者长期黏膜T细胞活化与归巢表型

Long-term mucosal T cell activation and homing phenotypes in recipients of an Ad5-vectored HIV vaccine.
PubMed 文献 · Vaccine · 2020-07-14

本研究对曾接种MRKAd5/HIV-1或安慰剂的参与者,在约两年后采集血液和结肠黏膜活检,比较细胞表型和胞内细胞因子应答。结果显示疫苗接种未导致黏膜CD4+或CD8+ T淋巴细胞活化状态的长期改变,未发现接种两年后HIV易感性增强的依据。

要点

  • MRKAd5/HIV-1接种约两年后黏膜T细胞活化状态无长期改变。
  • 基线Ad5血清状态不影响黏膜T细胞活化或归巢标志物表达。
  • 未发现疫苗接种两年后HIV易感性增强的免疫学依据。

核心结论

  • 接种MRKAd5/HIV-1未导致黏膜CD4+或CD8+ T淋巴细胞活化状态的长期改变,与基线Ad5血清状态无关。
  • 研究结果未揭示疫苗接种两年后HIV易感性增强的免疫学基础。

研究设计与样本

  • 对HVTN 071和HVTN 502/Merck 023中接种安慰剂或MRKAd5/HIV-1的参与者,在约两年后两个时间点(间隔约六个月)采集静脉血和经柔性乙状结肠镜行结肠黏膜活检。
  • 分离单核细胞后,比较疫苗组与安慰剂组、基线Ad5血清反应阳性与阴性者的细胞表型和胞内细胞因子应答。

主要发现

  • 肠黏膜单核细胞(GMMC)上活化与归巢标志物的表面表达高于外周血单核细胞(PBMC)(p < 0.01),但未受基线Ad5血清状态或MRKAd5/HIV-1接种显著影响。
  • 对疫苗抗原刺激的胞内细胞因子(ICS)应答频率和强度均低。
  • CD4+对载体抗原的应答在GMMC中比PBMC更常见(p < 0.01)。
  • CD8+对HIV gag插入抗原的应答在Ad5血清阳性者中比Ad5血清阴性者更频繁(p = 0.03)。

临床怎么用

  • 为Ad5载体HIV疫苗长期黏膜免疫安全性提供证据,未提示接种两年后黏膜T细胞活化异常。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Vaccine-induced mucosal immune responses may be critical for protection against HIV infection, but may also result in short or long-term changes that enhance susceptibility to infection in some individuals, such as those with baseline seroreactivity to vaccine vector antigens. We examined cellular immune responses in blood and gut mucosal tissue roughly two years following vaccination with placebo or the Step study vaccine MRKAd5/HIV-1. METHODS: Participants vaccinated with either placebo or MRKAd5/HIV-1 during participation in HVTN 071, and HVTN 502/Merck 023 underwent phlebotomy and colonic mucosal biopsies via flexible sigmoidoscopy at two timepoints roughly six months apart. After isolation of mononuclear cells, we compared cellular phenotypes and intracellular cytokine responses in vaccine and placebo recipients with and without baseline serological reactivity to Ad5. RESULTS: Surface expression of activation and gut-homing markers were elevated on CD4 + and CD8 + gut mucosal mononuclear cells (GMMC) in comparison with PBMC (p < 0.01), but were not significantly affected by baseline Ad5 serostatus or receipt of MRKAd5/HIV-1. ICS responses to stimulation with vaccine antigens were of low frequency and magnitude. Ad5 vector responses were seen in vaccinees and baseline seropositive individuals. CD4 + responses to vector antigens were more common in GMMC than PBMC (p < 0.01) and CD8 + responses to HIV gag insert antigens were more frequent in Ad5 seropositive than Ad5 seronegative individuals (p = 0.03). CONCLUSION: Vaccination with the Ad5 vectored candidate HIV vaccine MRKAd5/HIV-1 does not lead to long-term changes in the activation state of mucosal CD4 + or CD8 + T lymphocytes regardless of baseline Ad5 serostatus. The findings of this study do not reveal a basis for enhanced susceptibility to HIV infection two years post vaccination.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Curlin ME, Shao J, Diaz G, et al. Long-term mucosal T cell activation and homing phenotypes in recipients of an Ad5-vectored HIV vaccine. Vaccine. 2020. PMID: 32680773. doi:10.1016/j.vaccine.2020.06.043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。